The global demand for breakthrough cancer treatments is colliding with a dangerous reality: a fast-growing counterfeit drug trade. A major crackdown in Delhi has exposed how fake versions of high-value therapies like Keytruda are infiltrating supply chains and putting patients at risk.

The case is not just a law enforcement story. It’s a warning about gaps in drug access, oversight, and affordability that are creating space for criminal networks to thrive.

What happened in the Delhi fake cancer drug racket?

In 2024, the Delhi Police uncovered a large-scale operation producing counterfeit cancer drugs across Delhi-NCR.

Authorities arrested multiple individuals linked to a syndicate that allegedly manufactured and sold fake chemotherapy and immunotherapy vials.

Key findings from the investigation

• Over 140 fake vials seized, valued at around ₹4 crore
• Estimated total sales exceeding ₹25 crore over two years
• Operations spread across Delhi, Gurugram, Uttar Pradesh, and Bihar
• More than 200 patients believed to have been affected

The scale of the operation highlights how sophisticated and organized counterfeit drug networks have become.

How did the counterfeiters operate?

The method was disturbingly simple and highly effective.

Step-by-step breakdown

1. Procurement of genuine vials
   Empty or partially used vials of branded drugs like Keytruda were sourced by purchasing or stealing them.
2. Refilling with fake substances
   The vials were filled with inexpensive liquids such as:
   • Dextrose
   • Fluconazole
3. Resealing and repackaging
   Professional machinery was used to reseal the vials, making them appear authentic.
4. Resale at premium prices
   The fake drugs were sold through pharmacies and online channels for ₹1 lakh to ₹3 lakh per vial.

Why this worked

• Patients trust branded packaging
• High demand creates urgency and reduces scrutiny
• Limited supply of genuine drugs pushes buyers to alternative channels

Why drugs like Keytruda are being targeted

Not all medicines attract counterfeiters. High-value, life-saving drugs are prime targets.

What makes Keytruda vulnerable?

• High cost: ₹1.5–₹2 lakh per vial in India
• High demand: Used in multiple aggressive cancers
• Limited availability: Supply constraints increase desperation
• Patent protection: Keeps prices elevated

Developed by Merck & Co., Keytruda is a form of immunotherapy that helps the body’s immune system fight cancer cells. Its effectiveness has made it widely sought after, and that demand has created a parallel illegal market.

Other targeted drugs

The racket also reportedly involved counterfeit versions of:

• Opdyta
• Tecentriq
• Imfinzi
• Perjeta

These are all advanced therapies used in oncology, often costing lakhs per treatment cycle.

The human cost: when fake drugs turn fatal

Behind the numbers are real patients and families.

Investigators reported cases where:

• Patients paid lakhs for treatments that contained no active cancer-fighting agents
• Families spent life savings on ineffective or harmful substitutes
• At least one death has been linked to the counterfeit drugs

In some instances, patients unknowingly received antifungal medication instead of cancer therapy, delaying proper treatment and worsening outcomes.

Why this is especially dangerous

• Cancer treatments are time-sensitive
• Delays can allow disease progression
• Fake drugs can cause additional health complications

This isn’t just fraud. It’s a direct threat to life.

How did hospital insiders become involved?

One of the most troubling aspects of the case is the alleged involvement of hospital staff.

Reports indicate that employees from major institutions, including oncology units, may have helped source empty vials.

What this reveals

• Weak internal controls in handling medical waste
• Lack of tracking for high-value drug containers
• Insider access being exploited by criminal networks

This raises urgent questions about accountability within healthcare systems.

Why counterfeit cancer drugs are rising globally

The Delhi case reflects a broader global trend.

Key drivers

• Rising cancer burden worldwide
• High cost of innovative therapies
• Supply chain gaps in developing markets
• Growth of online pharmaceutical sales

According to global health agencies, counterfeit medicines are a growing problem, particularly in regions where regulation and enforcement are uneven.

What can patients and families do to stay safe?

While systemic reform is essential, there are steps individuals can take to reduce risk.

Safety checklist for patients

• Buy medicines only from verified, licensed pharmacies
• Avoid deals that seem unusually discounted
• Check packaging for tampering or irregularities
• Verify batch numbers with manufacturers when possible
• Consult doctors before purchasing from alternative sources

Role of hospitals and regulators

• Strengthen tracking of drug vials and disposal systems
• Implement stricter audits in oncology departments
• Crack down on unauthorized online sales

Why this crisis demands urgent attention

The counterfeit drug trade thrives where demand meets desperation. High-cost, life-saving treatments like Keytruda represent both a medical breakthrough and a market vulnerability.

Unless access improves and oversight strengthens, similar rackets are likely to emerge again. The stakes are clear. This is not just about fake medicine. It’s about trust in healthcare systems and the safety of patients fighting for their lives.

TL;DR

• A Delhi crackdown exposed a ₹25 crore fake cancer drug racket
• Counterfeit vials of Keytruda and similar drugs were sold to patients
• Fake medicines contained substances like dextrose and antifungals
• Over 200 patients may have been affected; at least one death reported
• High drug costs and demand are fueling the counterfeit market
• Stronger regulation and patient awareness are critical